2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216403s000lbl.pdf. Accessed 9 Mar 2023. CSL Vifor. CSL Vifor and Travere Therapeutics announce EMA has accepted for review the Conditional Marketing Authorization application for sparsentan for the treatment of IgA Nephropathy [...
-在20℃至25℃下储存,允许在15℃至30℃范围内波动。 -将本品储存在原装容器中。 参考链接:https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216403s000lbl.pdf上一篇:莫博赛替尼(mobocertinib)-LuciMob 下一篇:斯帕森坦(sparsentan)-LUCISETA 免...
ETMerck’s Welireg is up for a potential FDA label expansion by May 26. The agency granted a priority review to the company's bid to expand the drug's label into advanced, unresectable, or metastatic pheochromocytoma and paraganglioma (PPGL), which would add to currently approved indications ...